Using my INNOVO®

Here's a list of frequently asked questions about using the device. If you still can't find the answer to your question, feel free to contact us on info@restorethefloor.com or call us on 0800 028 5687 FREE and we’ll be happy to help.

  • If you receive this error message when using INNOVO®, you should check the connections between the garments and the lead. These need to be firmly connected – you should feel 2 clicks when connecting these together. Ensure that the connectors are fully clicked together and commence your treatment session.

  • To get the best results from your INNOVO® it’s important that you use the correct size. You will need to take your hip measurement around the widest part of your buttocks. Then use the sizing guide below to find out which size garment you should use. 

     

  • For details on how to put on the garments, watch our INNOVO® instruction video or download the INNOVO® Quick Start guide and instruction manual.

  • If you find that you leak when you cough, sneeze and exercise, this is known as stress incontinence. This happens when the pelvic floor muscles that support the bladder are weakened or damaged.

    Programme 1 strengthens the pelvic floor by delivering targeted impulses to improve your pelvic floor muscle tone, strength, endurance and overall control. If you find that you often experience a sudden and urgent desire to pass urine, and sometimes leak, this is known as urge incontinence. This is caused by over-activity in the muscle mechanism that controls bladder function.

    Programme 2 delivers a gentle signal to the nerve that controls this muscle mechanism, helping to control the over-activity. It is common to experience symptoms of both urge and stress incontinence. This condition is called mixed incontinence. Usually, one type is more bothersome than the other.

    Treatment for mixed incontinence consists of a combination of the Programme 1 and Programme 2. Please refer to the instruction manual for details of each Innovotherapy programme.

  • You can use INNOVO® in one of the following positions:

    • Standing, with your upper body slightly tilted forward. You may wish to rest your hands on a surface for support
    • Lying flat face-up or in a reclining position with your knees bent and your feet flat

    For more information watch our INNOVO® instruction video.

  • How we actually feel the intensity differs from one person to the next. As a guide and for the best treatment outcome we recommend that you should aim to reach a training intensity level of 70-75. This level may be beyond your comfort levels at first, which is fine. Most people require a short period of time to familiarise themselves with the feeling of the stimulation so only go as far as you feel comfortable (E.g. 30-40, whatever it may be) and then regularly assess your ability to go up another level or two. If you feel comfortable you can increase the intensity beyond 75, however ensure you do not exceed your comfort level. Effective stimulation should be strong but never uncomfortable.

  • Don’t be concerned if you cannot reach the recommended intensity level during your first treatment session as it may take several sessions for you to reach this level. Some people may not reach this level at all, which is fine. Your aim is to reach a level that delivers as strong a contraction to the pelvic floor as possible without causing discomfort or pain.
  • The treatment session is complete when the counter reaches zero. The display will flash “00:00”, the stimulation will be reduced to zero and the controller will beep to indicate the end of the session.
  • Yes, some people will experience pelvic floor muscle contraction at intensity level 60. Once the pelvic floor is being contracted, the treatment will be effective but the stronger the contraction the better the results. For the best results it is important that you do 5 sessions a week for 12 weeks.

  • It is not necessary to do pelvic floor exercises while the programme is running. However you can continue with your pelvic floor exercises any other time.
  • If using INNOVO® to treat stress incontinence (Programme 1) you should use it 30 minutes per day, 5 days per week. If using INNOVO® to treat urge incontinence (Programme 2) you should use it approximately 3 or 4 times a week, every second day. If you want to treat mixed incontinence you should alternate between Programme 1 and Programme 2 every other day.

    Stress incontinence programme 1:

    Urge incontinence programme 2:

    Mixed incontinence:

  • We recommend that you use INNOVO® for a maximum of 30 minutes per day – the same length of time as it takes to complete one full treatment session. If for any reason you find yourself unable to complete a 30 minute session you can break it up into shorter sessions which can be done more frequently e.g. 15 mins done twice daily or 10 mins done 3 times per day. The goal is to complete 30 minutes per day in total.

  • An Innovotherapy programme to maintain a  healthy pelvic floor after 12 weeks will depend on the individual and their specific condition and improvement rate. As a general guide we would recommend you reduce the use of INNOVO® from 5 days a week after 3 months to 1-2 times a week. This will ensure that the results achieved during the 12 week programme will be sustained. One of the big advantages of using INNOVO® is that your awareness of your pelvic floor will have increased so you can also maintain a healthy pelvic floor by doing daily pelvic floor exercises after this time.

1) Soeder S, Tunn R. (2012) - Neuromuscular Electrical Stimulation (NMES) of the Pelvic Floor Muscles using a Non-Invasive Surface Device in the Treatment of Stress Urinary Incontinence (SUI); A Pilot Study. IUGA Poster Presentation Conference, Dublin, Ireland (2013)

2) http://www.webmd.com/urinary-incontinence-oab/america-asks-11/stress

3) Continence Foundation of Australia, Key statistics http://www.continence.org.au/pages/key-statistics.html

4) Arnold H. Kegel "Sexual Functions of the Pubococcygeus Muscle "Western Journal of Surgery, Obstetrics & Gynecology, 60, pp. 521-524, 1952

5) http://www.ncbi.nlm.nih.gov/pubmed/20087572